Na Li
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Sexual Dimorphism and Age Effects in CKD and Type 2 Diabetes in the CONFIDENCE Trial.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: March 27, 2026
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
Journal: Journal of the American Society of Nephrology : JASN
Published: September 26, 2025
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: August 01, 2025
Early Hemodynamic Safety of Simultaneous Initiation of Finerenone and Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes: The CONFIDENCE Trial.
Journal: Journal of the American College of Cardiology
Published: July 25, 2025
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: July 18, 2025
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
Journal: The New England journal of medicine
Published: June 05, 2025
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: December 10, 2024
Showing 1-8 of 8
Last Updated: 09/26/2026